First effort is focused on a transgenically produced recombinant form of human factor VIIa.
GTC Biotherapeutics entered into a strategic collaboration with LFB Biotechnologies to develop selected recombinant plasma proteins and Mabs using GTC’s transgenic production platform. A Joint Steering Committee will agree on product development, as well as commercialization plans.

The first program in this collaboration is for development of a transgenically produced recombinant form of human factor VIIa (rhFVIIa). GTC will be responsible for development of the production system and will retain exclusive commercial rights to the products in North America. LFB Biotechnologies will be responsible for clinical development and regulatory review of the first program of this collaboration and will have exclusive commercial rights in Europe. GTC and LFB Biotechnologies will hold co-exclusive rights in the rest of the world.

Previous articleBerna Products Sold to Crucell for $16.5M
Next articleMacroGenics Receives NIAID $50-M Award Targeting West Nile Virus